摘要:
The invention concerns RAC-PK and fragments thereof, as well as activators and inhibitors of RAC-PK for use as medicaments, particularly in the treatment of diseases concerned with abnormalities in processes modulated by insulin, such as cellular proliferation, insulin deficiency and/or excess blood sugar levels. Moreover, the invention provides RAC-PK for use in screening potential mimics or modulators thereof. A method for screening for agents capable of affecting the activity of GSK3 is also disclosed. The invention further provides a screening kit comprising the RAC-PK as an active principle, and a method for screening compounds which are candidate mimics or modulators of RAC-PK activity comprising detecting specific interactions between the candidate compounds and RAC-PK. There is also provided a process for activating RAC-PK comprising treatment thereof with a phosphatase inhibitor.
摘要:
A method for assessing the effect of a test compound on LRRK2 in a cell-based system, the method comprising the steps of a) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the phosphorylation state of Ser910 and/or Ser935 of the LRRK2; and/or b) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the binding of the LRRK2 to a 14-3-3 polypeptide. The method is considered to be useful in assessing the effect of putative LRRK2 inhibitors in cell based systems, including in vivo systems.
摘要:
A method for selecting a compound for modulating the activity of phosphoinositide dependent protein kinase 1 (PDKI) is provided. The method may comprise modelling a three dimensional structure of a plurality of molecules in a computer, comparing with the three dimensional structure of the compounds with that of a reference structure such as at least part of a protein kinase catalytic domain of PDK1, and selecting the compound based on a predicted interacting ability of the molecules to the protein kinase catalytic domain. Also a method for selecting a compound for modulating the activity of hydrophobic pocket containing protein kinase is provided. In this method, the reference structures may be one or more of a phosphate binding pocket of PDK1, a hydrophobic pocket of PDK1, and αC helix or region interacting therewith of PDK1.
摘要:
A method for identifying a compound for use in modulating, for example promoting, the activation or phosphorylation of AMPK (AMP-activated protein kinase) or AMPK subfamily member in a cell, the method comprising the steps of (1) determining whether a test compound modulates, for example promotes, the protein kinase activity of LKB1 and (2) selecting a compound which modulates, for example promotes, the protein kinase activity of LKB1. The protein kinase activity may be tested using AMPK or an AMPK subfamily member, or a peptide encompassing the T-loop region of AMPK or an AMPK subfamily member. The LKB1 may be in a preparation or complex with STRAD and/or M025, which has much greater kinase activity than LKB1 in the absence of these accessory proteins. The LKB1, STRAD or M025 may be recombinant. The AMPK subfamily member may be AMPKα1, AMPKα2, NUAK1, NUAK2, BRSK1, BRSK2, SIK, QIK, QSK, MARK1, MARK2, MARK3, MARK4 or MELK.
摘要:
A method for assessing the effect of a test compound on LRRK2 in a cell-based system, the method comprising the steps of a) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the phosphorylation state of Ser910 and/or Ser935 of the LRRK2; and/or b) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the binding of the LRRK2 to a 14-3-3 polypeptide. The method may comprise or further comprise the step of assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the subcellular location of LRRK2. The method is considered to be useful in assessing the effect of putative LRRK2 inhibitors in cell based systems, including in vivo systems.
摘要:
A method for assessing the effect of a test compound on LRRK2 in a cell-based system, the method comprising the steps of a) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the phosphorylation state of Ser910 and/or Ser935 of the LRRK2; and/or b) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the binding of the LRRK2 to a 14-3-3 polypeptide. The method may comprise or further comprise the step of assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the subcellular location of LRRK2. The method is considered to be useful in assessing the effect of putative LRRK2 inhibitors in cell based systems, including in vivo systems.
摘要:
The present invention relates to methods of altering the substrate specificity of PDK1, methods of identifying compounds which modulate the activity of PDK1 and methods of using PDK1 having altered substrate specificity.
摘要:
A method for identifying a compound for modulating the cellular activity or location of PTPL1, comprising the step of identifying a compound that modulates the interaction of PTPL1 with TAPP; or which modulates or mimics the interaction of TAPP with Ptdlns(3, 4)P2; or which modulates the cellular location of TAPP. A method of treating a patient with diabetes or in need of inhibition of apoptosis, for example in the treatment of ischaemic disease, wound healing or nerve regeneration, wherein the patient is administered an effective amount of a compound that inhibits the interaction of PtdIns(3, 4)P2 with TAPP or that inhibits the interaction of TAPP with PTPL1. A method of treating a patient in need of promotion of apoptosis, for example in treating cancer or in the resolution of inflammation, wherein the patient is administered an effective amount of a compound that promotes the interaction of TAPP with PtdIns(3, 4)P2 or that mimics the effect of PtdIns(3, 4)P2 on TAPP, or that promotes the interaction of TAPP with PTPL1.
摘要:
A method for identifying a compound expected to be useful in modulating, for example inhibiting, LRRK2 protein kinase activity, the method comprising the steps of (1) determining whether a test compound modulates, for example inhibits, the protein kinase activity of a LRRK2 polypeptide on a substrate polypeptide and (2) selecting a compound which modulates, for example inhibits, the said LRRK2 polypeptide protein kinase activity, wherein the substrate polypeptide comprises the sequence (W/F/R/K)(W/F/R/K)(R/K)(F/W/H/R)(Y/W/R)(S/T)(L/V/I) (R/K)(R/K)(A/Y) or (W/R)(X)(X)(F/Y/H/T)(Y/W/R)(T)(X)(R/T)(R)(X), where X represents any amino acid. Such a compound may be useful in treating Parkinson's Disease or Parkinsonism. The substrate polypeptide may consist or comprise the sequence RLGWWRFYTLRRARQGNTKQ.
摘要翻译:鉴定预期可用于调节例如抑制LRRK2蛋白激酶活性的化合物的方法,所述方法包括以下步骤:(1)测定测试化合物是否调节例如抑制LRRK2多肽的蛋白激酶活性 (2)选择调节例如抑制所述LRRK2多肽蛋白激酶活性的化合物,其中所述底物多肽包含序列(W / F / R / K)(W / F / R / K )(R / K)(F / W / H / R)(Y / W / R)(S / T)(L / V / I)(R / K)(R / K)(A / Y) (W / R)(X)(X)(F / Y / H / T)(Y / W / R)(T)(X)(R / T)(R)(X) 酸。 这种化合物可用于治疗帕金森病或帕金森综合征。 底物多肽可以包含或包含序列RLGWWRFYTLRRARQGNTKQ。